ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1079

TSPO Mediates Tubulointerstitial Fibrosis and Kidney Inflammation After Unilateral Ureteral Obstruction

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Feng, Yuchen, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
  • Yiu, Wai Han, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
  • Lok, Sarah W.Y., The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
  • Zou, Yixin, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
  • Ma, Jingyuan, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
  • Lai, Kar Neng, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
  • Tang, Sydney C.W., The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
Background

Tubulointerstitial fibrosis is a hallmark of chronic kidney disease (CKD) and predicts progression to kidney failure. A better understanding of its pathogenetic mechanisms is required for designing novel and effective treatments for this irreversible pathological process. Translocator protein (TSPO), located on the outer mitochondrial membrane, is associated with renal tubular cell death and regeneration in acute kidney injury. However, the role of TSPO in progressive CKD remains unknown.

Methods

Unilateral ureteral obstruction (UUO) or sham operation were performed on C57BL/6J mice to establish progressive tubulointerstitial fibrosis. TSPO antagonist PK11195 or vehicle was administrated daily to UUO mice for 7 days starting on the day of surgery. Kidneys were harvested for histology, inflammation and fibrosis.

Results

Histopathologically, tubular damage induced by UUO was reversed by PK11195 treatment. Induction of TNF-α, CCL-2 and IL-1β mRNA in the UUO kidney was reduced in PK11195 group compared to vehicle control. UUO-induced collagen deposition, as demonstrated by Masson's Trichrome and Picrosirius Red staining, was decreased after PK11195 treatment, and immunohistochemical analysis further confirmed significant reduction of Col-1 and Col-3 expression. Furthermore, PK11195 treatment downregulated UUO-induced fibronectin, α-SMA, vimentin and TGF-β levels by Western blotting.

Conclusion

We provided novel data to show that blockade of TSPO activity could alleviate kidney fibrosis and inflammation in murine UUO, suggesting that TSPO could play an important role in regulating progressive kidney disease.
Funding: Health and Medical Research Fund (HMRF) of Hong Kong (grant no. 09202356); Hong Kong Society of Nephrology Research Grant 2022

Funding

  • Government Support – Non-U.S.